Tu, H., Wang, Y., Liu, H., Huang, D., Ren, P., Ning, F., Shi, X., Liu, B., Yang, H., Wang, L., Feng, H., Liu, C., Zhong, X., Zhang, M., Sun, Y., Gao, A., Zhang, S., Du, J., Ye, J., Wu, Y. (2026). IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8586